Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells.
about
Interferon (IFN) and Cellular Immune Response Evoked in RNA-Pattern Sensing During Infection with Hepatitis C Virus (HCV)Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunityA systems biology approach to the analysis of subset-specific responses to lipopolysaccharide in dendritic cells.Folate-modified Chitosan Nanoparticles Containing the IP-10 Gene Enhance Melanoma-specific Cytotoxic CD8(+)CD28(+) T Lymphocyte ResponsesMulti-step regulation of interferon induction by hepatitis C virus.Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer.Interferon regulatory factor 3 in adaptive immune responses.A novel nanoparticle containing neuritin peptide with grp170 induces a CTL response to inhibit tumor growth.Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity.Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia.Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy.Role of type I interferon signaling in human metapneumovirus pathogenesis and control of viral replication.Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy.TAMable tumor-associated macrophages in response to innate RNA sensing.The TLR3/TICAM-1 signal constitutively controls spontaneous polyposis through suppression of c-Myc in Apc Min/+ mice.Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors.Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b+Ly6G+ intratumor myeloid cells through the TICAM-1 signaling pathway.Tumor cell death by pattern-sensing of exogenous RNA: Tumor cell TLR3 directly induces necroptosis by poly(I:C) in vivo, independent of immune effector-mediated tumor shrinkage.Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy.Adjuvanting influenza hemagglutinin vaccine with a human pulmonary surfactant-mimicking synthetic compound SF-10 induces local and systemic cell-mediated immunity in mice.Current challenges for cancer vaccine adjuvant development.Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model.Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands.
P2860
Q26778005-4CB2A1D9-3D0C-4A9B-B488-EF9381A97F35Q26782131-77C8656D-703A-459F-B622-F783A0560E4BQ35192110-C75CFF17-D862-448D-9420-37C2F8539D41Q36723775-9E492BD6-10EE-4CC3-B0AF-DD7AA9CB22BAQ38071909-BF748891-4A91-41DD-8515-3D6027FA90E5Q38081981-FB63DEFB-5D2E-413F-AB9B-6BB18448AF52Q38216206-3F113AB0-4B84-4807-875B-B448C78211C0Q38842410-2256CFB6-290E-4B2B-8734-81FDB24E8877Q39192241-B06BDA17-C7E0-4E21-ABB7-75687D2E150EQ39281091-3D042468-1BAA-48F1-97E6-551BD62DA9D3Q40994269-E234BA29-8281-44C9-88A0-1A37D5416F79Q41013010-A989A426-9B20-4772-831A-FEDD931E4717Q41073960-6DCBA407-18D2-4912-BB0C-8DC871499B14Q41475520-498080FB-802A-4ABD-B59E-BA070A25E2A8Q42563154-9947EF8D-4347-4AD3-983B-53AD6866CD88Q45716103-BA8CE0A4-87A3-4B7B-B5DF-A45C1C1F2F35Q46461063-77A51EFE-DF60-4FAE-A450-232C8508E577Q47113328-FE4AF965-9C43-4FEC-AFF6-BE5A6E02CA8BQ47236265-47305FB1-937B-4DF2-8895-78B9572605C0Q47548928-F4BC1E8C-5F41-4377-98CD-14D81E15564FQ48160317-9B911741-C3C1-495B-804E-EFFE44972FD0Q49710218-2631CD59-4E8D-4A05-A953-FF84A3C20433Q54943714-C3824F25-DEDC-4036-B219-6FA0E74FF4A8
P2860
Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cross-priming for antitumor CT ...... 1c(+)/CD8α(+) dendritic cells.
@ast
Cross-priming for antitumor CT ...... 1c(+)/CD8α(+) dendritic cells.
@en
type
label
Cross-priming for antitumor CT ...... 1c(+)/CD8α(+) dendritic cells.
@ast
Cross-priming for antitumor CT ...... 1c(+)/CD8α(+) dendritic cells.
@en
prefLabel
Cross-priming for antitumor CT ...... 1c(+)/CD8α(+) dendritic cells.
@ast
Cross-priming for antitumor CT ...... 1c(+)/CD8α(+) dendritic cells.
@en
P2093
P2860
P356
P1433
P1476
Cross-priming for antitumor CT ...... 11c(+)/CD8α(+) dendritic cells
@en
P2093
Hiroyuki Oshiumi
Masahiro Azuma
Misako Matsumoto
Tsukasa Seya
P2860
P304
P356
10.4161/ONCI.19893
P577
2012-08-01T00:00:00Z